RESUMEN
The CTX-M-1 group was found in 86.8% of the Escherichia coli isolates from Istanbul. A subset study revealed all isolates carrying bla(CTX-M-15) genes flanked by the insertion element ISEcp1. Plasmid typing of transconjugates carrying bla(CTX-M-15) showed that most isolates belonged to the Inc/rep FII group but that one isolate also belonged to the FI group.
Asunto(s)
Conjugación Genética , Escherichia coli/enzimología , Factor F/genética , Hospitales Universitarios , Plásmidos/genética , beta-Lactamasas/genética , Antibacterianos/farmacología , Cefotaxima/farmacología , Ceftazidima/farmacología , Escherichia coli/efectos de los fármacos , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/epidemiología , Infecciones por Escherichia coli/microbiología , Proteínas de Escherichia coli/genética , Humanos , Pruebas de Sensibilidad Microbiana , Reacción en Cadena de la Polimerasa , Prevalencia , Técnica del ADN Polimorfo Amplificado Aleatorio , Turquía/epidemiología , Resistencia betalactámicaRESUMEN
The purpose of this study was to type the Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolates recovered from cystic fibrosis (CF) patients by random amplified polymorphic DNA (RAPD)-PCR and to determine the antibiotic susceptibility of these strains. P. aeruginosa (n=49), and S. maltophilia (n=11) isolates which had been recovered from 16 and 8 patients, respectively, during a 1-year period were investigated. Three primers were used for RAPD-PCR typing. Antibiotic susceptibility testing of all isolates was performed by the disc diffusion method. RAPD-PCR analysis revealed 21 (P. aeruginosa) and 9 (S. maltophilia) different genotypes. According to the antimicrobial susceptibility results, the P. aeruginosa and S. maltophilia strains were cumulated into 24 and 11 groups, respectively. The CF patients were colonized or infected with P. aeruginosa strains of single or sometimes multiple genotypes which remained stable over several months. Our results also revealed that cross-colonization might be possible among the patients who are followed up at the same center. Piperacillin-tazobactam for P. aeruginosa and trimethoprim-sulfamethoxazole for S. maltophilia were found to be the most active antibiotics according to our results.
Asunto(s)
Antibacterianos/farmacología , Fibrosis Quística/microbiología , Pseudomonas aeruginosa/clasificación , Pseudomonas aeruginosa/efectos de los fármacos , Stenotrophomonas maltophilia/clasificación , Stenotrophomonas maltophilia/efectos de los fármacos , Fibrosis Quística/epidemiología , Genotipo , Infecciones por Bacterias Gramnegativas/epidemiología , Infecciones por Bacterias Gramnegativas/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Infecciones por Pseudomonas/epidemiología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/genética , Pseudomonas aeruginosa/aislamiento & purificación , Técnica del ADN Polimorfo Amplificado Aleatorio , Stenotrophomonas maltophilia/genética , Stenotrophomonas maltophilia/aislamiento & purificaciónRESUMEN
The activity of moxifloxacin, a new 8-methoxyquinolone, was compared in vitro with the activity of ciprofloxacin against clinical strains isolated from various sites of infection. The mode MIC values of moxifloxacin were superior to those of ciprofloxacin against Streptococcus pneumoniae, methicillin-susceptible and -resistant Staphylococcus aureus, Enterococcus spp., Escherichia coli and Acinetobacter spp., while ciprofloxacin was more active against Klebsiella pneumoniae and Pseudomonas spp. Both antibiotics had similar activity against Haemophilus influenzae, Moraxella catarrhalis and Enterobacter spp.
